Komori
Changes in Directors and Officers4553TOWA PHARMACEUTICAL CO.,LTD.Pharmaceuticals

Notice Regarding Changes in Officers

The Company has provisionally decided on 10 director candidates for the annual general meeting of shareholders scheduled for 24 June 2026. Most of the existing directors, including the current president, are candidates for reappointment. The proposed lineup includes 2 new director candidates and 1 additional outside director.

Worth reading
36Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Neutral
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Conditional
How definitive the wording is.

Who is moving to which position

Resolved 21 May 2026

Incoming appointee

2 items
Scheduled Appointment DateFollowing approval at the 70th Annual General Meeting of Shareholders scheduled for 24 June 2026
Nakamura Gōshi (中村 豪之)
Previous positionExecutive Officer, Head of the President's Office, and concurrently in charge of the Corporate Strategy Division
New positionDirectors (excluding directors serving as Audit and Supervisory Committee members)
Taniguchi Muneya (谷口 宗哉)
Previous positionSpecial Advisor, Mitsubishi UFJ Securities Holdings Co., Ltd. (current)
New positionDirector, Audit and Supervisory Committee Member
Date of birth6 June 1962 (Taniguchi Muneya (谷口 宗哉)); Nakamura Gōshi (中村 豪之): not disclosed
Because the names and counts do not correspond, they are shown as reported without linking the counts to individual names.
Directors after the change10Number
Filing as an independent officerTaniguchi Muneya (谷口 宗哉) is scheduled to be reported as an independent officer. Subject to approval of their reappointments, Eiki Norikazu (栄木憲和), Oishi Kaori (大石歌織) and Ando Nobuki (安藤伸樹) are scheduled to continue to be reported as independent officers.
Shareholders’ meeting approvalYes. The proposal for the election of directors at the 70th Annual General Meeting of Shareholders scheduled for 24 June 2026.
Independent officers are outside officers registered with the exchange as having no conflict of interest with general shareholders.
Who is moving to which position
ItemDetails
Resolution date21 May 2026
Scheduled Appointment DateFollowing approval at the 70th Annual General Meeting of Shareholders scheduled for 24 June 2026
Name of appointeeNakamura Gōshi (中村 豪之), Taniguchi Muneya (谷口 宗哉)
Appointee's new positionDirectors (excluding directors serving as Audit and Supervisory Committee members), Director, Audit and Supervisory Committee Member
Appointee's previous positionExecutive Officer, Head of the President's Office, and concurrently in charge of the Corporate Strategy Division, Special Advisor, Mitsubishi UFJ Securities Holdings Co., Ltd. (current)
Appointee's date of birth6 June 1962 (Taniguchi Muneya (谷口 宗哉)); Nakamura Gōshi (中村 豪之): not disclosed
Number of directors after the change10 directors (including 4 outside directors)
Filing as an independent officerTaniguchi Muneya (谷口 宗哉) is scheduled to be reported as an independent officer. Subject to approval of their reappointments, Eiki Norikazu (栄木憲和), Oishi Kaori (大石歌織) and Ando Nobuki (安藤伸樹) are scheduled to continue to be reported as independent officers.
Subject to Approval by the General Meeting of ShareholdersYes. The proposal for the election of directors at the 70th Annual General Meeting of Shareholders scheduled for 24 June 2026.
Items this document does not state (12)
Date of departureYear the appointee joined the CompanyNumber of shares held by the appointeeName of departing officerFormer position of departing officerNew position of departing officerReason for departureWhether the incumbent will remain in officeReason for changeReasons for appointmentDetails of organizational changesChange in Corporate Governance Structure

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The company has not provided specific reasons for the changes.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding Changes in Officers | TOWA PHARMACEUTICAL CO.,LTD. (4553) timely disclosure | Komori